Which treatment in the optic neuritis treatment trial (ONTT) had the highest rate of recurrence
**Question:** Which treatment in the optic neuritis treatment trial (ONTT) had the highest rate of recurrence
**Core Concept:** The Optic Neuritis Treatment Trial (ONTT) is a clinical trial designed to evaluate the efficacy of different treatments for acute optic neuritis, an inflammation of the optic nerve leading to visual disturbances. The study compares the recurrence rate in patients receiving different treatments.
**Why the Correct Answer is Right:** In the ONTT, the control group (Option D) received placebo treatment, meaning they received a seemingly harmless substance without any therapeutic effect. In this case, the placebo treatment does not provide any protection against the optic neuritis recurrence, leading to a higher recurrence rate compared to active treatments.
**Why Each Wrong Option is Incorrect:**
A. Option A (Interferon beta-1a) is an active treatment that has been shown to reduce the risk of optic neuritis recurrence. As a result, patients receiving interferon beta-1a have a lower recurrence rate compared to the control group.
B. Option B (Methotrexate) is also an active treatment in the ONTT. It has been demonstrated to decrease the risk of optic neuritis recurrence. Thus, patients receiving methotrexate have a lower recurrence rate compared to the control group.
C. Option C (Azathioprine) is an active treatment in the ONTT. It has been shown to reduce the risk of optic neuritis recurrence. Consequently, patients receiving azathioprine also have a lower recurrence rate compared to the control group.
D. The control group (Option D) received a placebo treatment, which does not provide any therapeutic effect. As a result, patients in the control group have a higher recurrence rate compared to those receiving active treatments.
**Clinical Pearl / High-Yield Fact:** The ONTT provides valuable information for the management of optic neuritis patients. The study demonstrates the importance of early and appropriate treatment to reduce the risk of optic neuritis recurrence. This understanding helps guide clinical decision-making in optic neuritis management, ensuring optimal patient care and outcomes.